The Severity and Pattern of Emesis following Different Cytotoxic Agents

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 26-31

  Martin, Miguel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Emetic pattern; Non cisplatin containing chemotherapy; Pattern of emesis

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; FLUOROURACIL; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; HUMANS; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; VOMITING;

EID: 0029789099     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227637     Document Type: Article

References (16)

1. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J: Comparison of the 5-hydroxytrypta-mine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dosc mctocolopramidc in the control of cisplatin-induced cmesis, N Engl J Med 1990;322:816-821.
2. Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, Wcrthcim MS, Kelscn DP: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dosc cisplatin, J Clin Oncol 1985:3:1379-1384.
3. Martin Jimenez M, Diaz-Rubio Garcia E: Cur-so espontaneo de la emesis inducida por cispla-tino y evaluation preliminar de mctocloprami-da cn bajas dosis intravenosas, Oncologia (Madrid) 1984;9:223-228.
4. Gandara DR, Harvey WH, Monaghan GG, Pcrcz EA, Hesketh PJ: Delayed emesis following high-dose cisplatin: A double-blind randomized comparative trial of ondansetron versus placebo, Eur J Canccr 1993;29A(suppl 1): S35-S38.
5. Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenberg WN, Kinnier WJ, Johnson DW, Sancilio LF, Ward JW: Antagonism of cisplatin-induced cmesis by metoclopramide and dazopride through enhancement of gastric motility, Dig Dis Sci 1986;31:524-529.
6. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy, Ann Intern Med 1993;118:407-413.
7. Cubeddu LX, Pendergrass K, Ryan T, York M, Burton G, Mesnad M, Galvin D, Ciociola AA: Efficacy of oral ondansetron, a selective antagonist of 5-HTj receptors in the treatment of nausea and vomiting associated with cyclo-phosphamide-based chemotherapies, Am J Clin Oncol 1994;17:137-146.
8. Beck TM: The pattern of emesis following high-dose cyclophosphamide and the antiemetic efficacy of ondansetron, Anticancer Drugs 1995;6:1-6.
9. Martin Jimenez M, Diaz-Rubio E, Blazquer Encinar JC, Roman Santamaria JM, Gonzalez Larriba JL, Marotc R, Fores MA: Tolerancia, toxicidad y aceptacion del tratamiento quimio-tcrapico FAC (5-fluorouracilo, adriamicina y ciclofosfamida) en el cancer de mama, Analisis de 100 pacientes consecutivas, Neoplasia (Bare) 1988;5:8-14.
10. Fetting JH, Grochow LB, Folstcin MF, Ettin-ger DS, Colvin M: The course of nausea and vomiting after high-dose cyclophosphamide, CanccrTreat Rep 1982;66:1487-1493.
11. Morran C, Smith DC, Anderson DA, McArdle CS: Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of antiemetics, Br Med J 1979;i: 1323-1324.
12. Rosso R, Campora E, Cetto G, Fosser V, Ma-rangolo M, Oliva C: Oral ondansetron for the control of acute and delayed cyclophospha-mide-induced emesis, Anticanccr Res 1991; 11: 937-939.
13. Schmoll HJ: The role of ondansetron in the treatment of cmesis induced by non-cisplatin containing chemotherapy regimens, EurJ Cancer Clin Oncol 1989;25(suppl 1):S35-S39.
14. Martin M, Diaz-Rubio E, Sanchez A, Almena-rez J, Lopcz-Vega JM: The natural course of carboplatin-induced emesis, Acta Oncol 1990; 29:593-595.
15. Du Bois A: Pattern of emesis and urinary 5-HIAA excretion following different cytotoxic agents, Advances in optimising the control of emesis, Glaxo Satellite Symp ESMO, Lisbon, Nov 20,1994, pp 14-17.
16. Smith DB, Rustin GJ, Howells N, Lambert HE, McQuade B: A phase II study of ondansetron as anticmctic prophylaxis in patients receiving carboplatin for advanced ovarian cancer, Ann Oncol 1991;2:607-608.